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ABSTRACT
Background: Homologous recombination deficiency (HRD) measured using a 
genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib 
in ovarian cancer. We hypothesized that some oesophagogastric cancers will have 
high-LOH which would be prognostic in patients treated with platinum chemotherapy.
Methods: Diagnostic biopsy DNA from patients treated in the REAL3 trial was 
sequenced using the Foundation Medicine T5 next-generation sequencing (NGS) 
assay. An algorithm quantified the percentage of interrogable genome with LOH. 
Multidimensional optimization was performed to identify a cut-off dichotomizing the 
population into LOH-high and low groups associated with differential survival outcomes.
Results: Of 158 available samples, 117 were successfully sequenced; LOH was 
derived for 74 of these. A cut-off of 21% genomic LOH defined an LOH-high subgroup 
(n=10, 14% of population) who had median overall survival (OS) of 18.3 months (m) 
versus 11m for the LOH-low group (HR 0.55 95% CI 0.19-0.97, p= 0.10). Progression 
free survival (PFS) for LOH-high and LOH-low groups was 10.7m and 7.3m (HR 0.61 
(95% CI 0.21 – 1.09, p=0.09). Sensitivity analysis censoring operated patients (n=4), 
demonstrated OS of 18.3m vs. 10.2m (HR 0.43, 95% CI (0.20-0.92), p=0.02; PFS was 
10.5m vs. 7.2m (HR 0.55, (95% CI 0.26-1.17), p=0.09 for LOH-high and LOH-low.
Conclusion: HRD assessment using an algorithmically derived LOH signature 
on a standard NGS panel identifies oesophagogastric cancer patients with high LOH 
who have prolonged survival when treated with platinum chemotherapy. Validation 
work will determine the signature’s predictive value in patients treated with a PARP 
inhibitor and with platinum chemotherapy.
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INTRODUCTION
Homologous recombination (HR) is a complex 
process requiring the coordinated function of a number of 
genes products in order to repair double-stranded breaks 
in DNA [1]. This process is frequently deranged in cancer, 
where the classic example of homologous recombination 
deficiency (HRD) is provided by BRCA1/2 mutated 
tumours [2, 3]. Targeting HRD in BRCA mutant tumours 
using a synthetically lethal approach with poly ADP ribose 
polymerase (PARP) inhibitors has resulted in beneficial 
effects for patients in ovarian, breast and prostate cancer [4–
7]. However, HRD may also be present in tumours without 
BRCA mutations; similar to BRCA mutant tumours these 
cancers are often platinum sensitive and may also respond 
to other DNA damage targeting drugs [7–10]. Such BRCA 
wild-type HRD tumours have high levels of “genomic 
scarring”, which arises from the use of error prone DNA 
repair pathways when homologous recombination is 
compromised. One method for quantifying the amount 
of genomic scarring is to assess the extent of loss of 
heterozygosity (LOH; loss of one copy of a chromosomal 
region) across the tumour genome. Determination of HRD 
using LOH may have clinical implications; in the ARIEL2 
Part 1 (NCT01891344) trial of previously treated ovarian 
cancer, BRCA wild-type patients with high levels of LOH 
(LOH-high) treated with the PARP inhibitor rucaparib were 
more likely to respond to rucaparib therapy and had longer 
progression free survival compared to rucaparib-treated 
patients who were not LOH-high [7, 11].
Oesophagogastric cancer is a platinum sensitive 
disease in which several genomic and proteomic 
biomarkers associated with DNA repair defects have 
been identified. These include ATM loss, The Cancer 
Genome Atlas (TCGA) chromosomally unstable (CIN) 
subtype and a putative BRCA mutational signature 
[12–16]. Therefore we hypothesized that genomic 
LOH (as a measure of HRD) might be associated with 
prognosis in oesophagogastric cancer patients treated 
with platinum based chemotherapy. In order to examine 
this hypothesis we assessed genomic LOH in tumour 
samples from patients treated with epirubicin, oxaliplatin 
and capecitabine plus or minus panitumumab (EOX±P) 
in the REAL3 (Randomised Trial of EOX with or 
without Panitumumab in Advanced or Locally Advanced 
Oesophagogastric Cancer 3) Trial, (NCT00824785), and 
correlated LOH with survival in this patient cohort.
Details of the REAL3 trial have been previously 
described [17]. In brief, eligible patients had a diagnosis 
of locally advanced or metastatic oesophagogastric cancer 
and were treated with EOX (epirubicin, oxaliplatin and 
capecitabine) plus or minus panitumumab (a fully human 
monoclonal IgG2 anti-EGFR antibody). Patients treated 
with EOX-panitumumab had inferior overall survival 
compared with patients treated with EOX (HR 1.37, 95% 
CI 1.07-1.76; p=0.013).
RESULTS
Out of a total of 553 REAL3 patients 158 formalin-
fixed paraffin embedded (FFPE) tissue blocks with high 
tumour content (>30%) were available; these were sent 
for NGS analysis to Foundation Medicine (FM). There 
was no significant difference in clinicopathological 
characteristics, progression free survival or overall 
survival between patients who underwent sequencing for 
LOH assessment and those without (see Supplementary 
Data). Of the 158 samples, one duplicate sample from 
the same patient was excluded. This left 157 samples 
which were processed for NGS (see CONSORT figure, 
Supplementary Data). The sample storage time for 
selected archival samples was a median of 5 years (range 
4-9 years) and the quality of FFPE tissue blocks varied 
widely across the processed batch. Following review of 
tumor nuclei enumeration at FM, 5 samples were deemed 
to have too low tumour content and were excluded from 
further analysis. We observed attrition during NGS 
processing due to tissue quality in 35 samples (23%) 
and were able to sequence 117 samples successfully. 
The LOH inference was successfully performed for 74 
of the sequenced samples (63%) or 47% of the original 
biomarker analysis population. This is because inference 
of LOH is based on copy number estimation which 
requires adequately deep and relatively even coverage 
across the genome. In contrast to mutation calling, the 
sample quality requirements for copy number detection 
are higher. Since the REAL3 samples had not been fixed 
with NGS in mind, not all samples met the higher quality 
standards for LOH inference but were sufficient for 
mutation calling.
There was no difference in the proportion of samples 
which were successfully sequenced from each tumour site; 
however junctional and oesophageal tumours were more 
likely to have LOH successfully inferred than stomach 
cancer (73% and 66% vs 50% respectively). Table 1  
summarizes the number of samples sequenced and the 
proportion of samples which had LOH derived according 
to anatomical site.
The median percentage of genomic LOH inferred 
for all tumours was 11.9% (n=74) (Figure 1). According to 
anatomical site, the median percentage of LOH was 10.6% 
for stomach (n=18), 11.4% oesophagus (n=27) and 14.8% 
(n=29) for gastroesophageal junction tumours. These 
differences were not statistically significant (p>0.05). The 
median and mean % LOH according to anatomical site are 
shown in Figure 2.
Using the optimization of survival benefit as 
described in the methods section, the optimal survival 
benefit for LOH-high vs. LOH-low patients was found to 
be in patients with ≥ 21% genomic LOH. Using an LOH 
level of ≥ 21% to define the LOH-high group, 10 out of 
74 patients (14%) were classified as LOH-high. At this 
cut off, the median overall survival (OS) was 18.3 months 
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for the LOH-high subgroup compared to 11 months for 
the LOH-low subgroup. Using a Cox proportional hazards 
model, we derived the OS hazard ratio to be 0.55 (95% CI 
0.19-0.97), p= 0.10. At the same LOH cut off, progression 
free survival (PFS) was 10.7 months for the LOH-high 
group compared to 7.3 months for the LOH-low group. 
Using a Cox proportional hazards model, the PFS HR 
was 0.61 (95% CI 0.21 – 1.09), p=0.09. Figures 3 and 4 
illustrate the overall survival and progression free survival 
curves in LOH-high and LOH-low subgroups. In the 
sensitivity analysis in which operated patients (n=4) were 
censored at the time of potentially curative surgery OS of 
18.3m vs. 10.2m (HR 0.43, 95% CI (0.20-0.92), p=0.02) 
for LOH-high vs. LOH-low patients and and PFS was 
10.5m vs. 7.2m (HR 0.55, (95% CI 0.26-1.17), p=0.09) in 
the same subgroups (Figure 5, Figure 6).
MANOVA of these clinicopathological variables 
potentially associated with progression free and overall 
survival showed that of these parameters only disease 
extent have a statistically significant impact on both 
progression free and overall survival (Table 2). Extended 
confounding analysis and groupwise statistical testing 
established that the distributions of these clinical and 
prognostic parameters are not different between the LOH-
high and LOH-low groups (Table 3). The prognostic 
factors identified through MANOVA therefore confound 
the survival outcome of both groups equally and any 
additional findings can be attributed to the difference in 
LOH levels.
HRD can also be caused by variants in genes of the 
HR pathway that render the protein function impaired. 
Categories of variants that are deleterious to protein 
function include protein truncating mutations, splice 
site mutations, homozygous deletions and large protein 
truncating rearrangements. The Foundation Medicine T5 
NGS assay has been validated to detect these classes of 
variants. In the REAL3 samples sequenced here, several 
deleterious mutations in genes of the HR pathway were 
detected and are detailed in Table 4 : BRCA2 (n=1), ATM 
(n=6), ATR (n=1), CHK2 (n=1). Additionally, 101 of 117 
(86%) samples had mutations in the TP53 gene. There 
was no significant difference in %LOH, OS, and PFS 
between the TP53 mutated and wildtype populations, other 
mutant populations were considered too small to analyse 
separately.
DISCUSSION
In this analysis we identify a group of 
oesophagogastric cancer patients treated in the REAL3 
Figure 1: Distribution of genomic LOH across the samples analysed.
Table 1: Number of samples sequenced and LOH derived by anatomical site
Overall Stomach Oesophagus GOJ
Samples submitted 157 46 56 55
Samples sequenced 117 (75%) 36 (78%) 41 (73%) 40 (73%)
Samples with LOH 
derived
74 (47%) 18 (50%) 27 (66%) 29 (73%)
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trial who have high levels of genomic LOH measured 
using an algorithmic approach to DNA sequencing data 
performed on tissue obtained from routine diagnostic 
biopsies. Using a cut-off of 21% genomic LOH to define 
LOH-high, we demonstrate that patients with higher levels 
of LOH have a trend towards longer overall survival than 
Figure 2: Genomic loss of heterozygosity by tumour site.
Figure 3: Overall survival in LOH-high and LOH-low groups.
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those who are not LOH-high. When a small number of 
patients who underwent potentially curative surgery were 
censored in a sensitivity analysis, these findings reached 
statistical significance (HR 0.43, 95% CI (0.20-0.92), 
p=0.02) These findings are of interest for two reasons. 
Firstly, although the predictive power of the biomarker 
Figure 4: Progression free survival in LOH-high and LOH-low groups.
Figure 5: Overall survival in LOH-high and LOH-low groups with operated patients censored at time of potentially 
curative surgery.
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cannot be determined in the absence of a control group, 
high LOH may identify patients who are more likely to 
benefit from platinum based chemotherapy. Secondly, as 
LOH-high patients with ovarian cancer benefit from PARP 
inhibition more than LOH–low patients, it is possible that 
high LOH could be a biomarker predictive of sensitivity 
to PARP inhibitors in oesophagogastric cancer patients. 
While these hypotheses require prospective validation, 
they could lead to more effective biomarker selected 
therapies for oesophagogastric cancer, a disease which 
currently has a dismal prognosis [18, 19].
Platinum based chemotherapy is a standard first line 
treatment for patients with advanced oesophagogastric 
cancer [20–23]. To date, no biomarker is available to 
select which oesophagogastric cancer patients might 
benefit from chemotherapy. Many studies have evaluated 
germline polymorphisms associated with response to 
platinum and fluoropyrimidine chemotherapy, but none 
have demonstrated definitive or practice changing results 
[24–26]. Microsatellite instability may be a biomarker 
of chemosensitivity for gastric cancer patients treated 
with perioperative chemotherapy; however this is rare in 
proximal tumours and in the the metastatic setting [27, 15]. 
Therefore, with the exception of HER2 overexpression 
and trastuzumab treatment, useful biomarkers to stratify 
patients with oesophagogastric cancer for standard therapy 
Figure 6: Progression free survival in LOH-high and LOH-low groups with operated patients censored at time of 
potentially curative surgery.







Age (<=65 (44), >65 (29)) 0.83 0.64
Gender (M (7),F (67)) 0.18 0.35
Tumour Site (O, S, OGJ) 0.61 0.98
Disease extent (locally advanced (7), metastatic (67)) 0.04 0.01
WHO PS 0 (28), >0 (33), unknown (3) 0.23 0.25
Histological subtype (Intestinal (61), diffuse (7), Mixed (5), 
Unknown (1))
0.13 0.03
Treatment (EOX (38), EOX-P (36)) 0.37 0.67
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are lacking [28]. We suggest further evaluation of the 
LOH-high biomarker in clinical trials in patients with 
oesophagogastric cancer in order to validate our findings.
The genomic and transcriptomic landscape of 
oesophagogastric cancer has been intensively explored 
recently. The recently published oesophageal TCGA data 
suggests that oesophageal adenocarcinoma is molecularly 
almost indistinguishable from chromosomally unstable 
gastric cancer [15]. These cancers are characterized 
by gross genomic instability and frequent large scale 
chromosomal events such as kataegis and chromothripsis 
which can lead to defects in homologous recombination 
and acquisition of genomic scar [29]. Gastric cancer has 
previously been identified as having a comparatively high 
level of genomic scarring measured using not only LOH, 
but also quantified using other metrics such as telomeric 
allelic imbalances (NtAI) and large scale transitions 
(LST), both of which predict platinum sensitivity 
in triple negative breast cancer [10, 30, 31]. Thus, 
although the presence of the HRD tumour phenotype 
and its association with platinum sensitivity has been 
established by multiple different methodologies across 
several cancer types including gastric cancer, we are the 
first to demonstrate potentially better survival with the 
HRD phenotype in oesophagogastric cancer treated with 
platinum chemotherapy and do so in a well annotated 
phase III randomized trial population. Based on patterns 
of presentation, it is likely that most of our samples were 
collected from the primary tumour, however as this 
information was not collected systematically, we cannot 
comment on the relationship between LOH, primary 
tumours and metastases.
Recent seminal work has demonstrated that 
chromosomal instability drives metastasis independently 
of aneuploidy and has described increased levels 
chromosomal instability in a cohort of matched primary 
tumour and brain metastases, in addition to a series 
of matched breast cancer primaries and metastases 
[32]. Therefore it is possible that our work, which was 
conducted on primary tumours, could underestimate the 
level of LOH in gastroesophageal cancer metastasis. This 
also in turn provides a potential explanation for divergent 
responses of primary and metastatic sites to platinum 
chemotherapy.
PARP inhibitors have a well-defined role in ovarian 
cancer, the value of PARP inhibition in oesophagogastric 
cancer is less clear. The Phase III randomized phase III 
GOLD trial failed to demonstrate a statistically significant 
overall survival advantage for olaparib treated patients in 
intention to treat trial population (median OS 8.8 months 
vs. 6.9 months (HR = 0.79, P =.0262), although this 
may be in part due to a statistical correction for multiple 
primary endpoints [33]. Notably, patients who were 
ATM negative and treated with olaparib demonstrated 
substantially improved response rates compared to ATM 
negative patients treated with paclitaxel alone (ORR 4.24, 
p=0.0309), therefore PARP inhibitors may still be effective 
in the correct biomarker selected oesophagogastric 
cancer population [34]. Our biomarker may identify 
a complementary group of gastroesophageal cancer 
patients who are ATM positive, yet who could benefit 
from a DNA damage targeting therapeutic approach. The 
potential value of a DNA damaging targeting approach 
in oesophageal cancers is also demonstrated by a recent 
large whole genome sequencing study of oesophageal 
adenocarcinoma which identified three intrinsic genomic 
signatures, one of which was putatively sensitive to PARP 
inhibition; however functional and clinical validation of 
this finding is awaited [16].
One limitation of our study is the small proportion 
of tumours from the total trial population which were 
successfully sequenced; prior biomarker studies on the 
same population had exhausted much of the available 
tissue [35]. In particular, the modest number of patients 
included in survival analyses and the imbalance between 
LOH-high and low-groups could hinder comparisons 






Age (% <65 years) 61% (39) 50% (5) 0.87 (Gosset t-test)
Gender (% F) 8% (5) 20% (2) 1 (Fisher)
Tumour site O, S, GOJ
37.5% (24), 25% (16), 37.5% 
(24)
30% (3), 20% (2), 50% (5) 1 (Fisher)
Disease extent (% 
metastatic)
91% (58) 90% (9) 1 (Fisher)
WHO PS (0,1,2, unknown)
39% (25), 50% (32), 6% (4), 
5% (3)
30% (3), 70% (7), 0% 1 (Fisher)
Histological subtype 
(%intestinal)
80% (51) 100% (10) 1 (Fisher)
Treatment (EOX, EOX-P) 53% (34), 47% (30) 40% (4), 60% (6) 1 (Fisher)
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between the groups and inclusion of LOH status into the 
multivariate model. However, as there was no significant 
difference between the survival of patients included in this 
study and the original trial, we do not think this introduced 
significant bias. We also did not find any confounding 
effects from other clinicopathological variables. Finally, 
a further limitation of our work is the lack of a control 
group, as all patients in our study received platinum 
chemotherapy; the predictive versus prognostic value of 
the LOH signature will need to be evaluated in further 
research. We think that there is sufficient indirect evidence 
to support our hypothesis, which is that of genomic 
LOH (a measure of HRD), could be associated with 
clinical benefit from platinum based chemotherapy in 
oesophagogastric cancer.
In conclusion, in this study we present our results 
from deriving a genomic signature for high LOH in 
oesophagogastric cancer patients treated with platinum 
Table 4: Overview of HR pathway mutations detected
Gene Total number (%) samples Number of samples 
with known deleterious 
mutation
Number of samples with 
mutation of unknown 
significance
ATM 13 (11%) 6 7
ATR 8 (7%) 1 7
ATRX 5 (4%) 2 3
BARD1 6 (5%) 6
BLM 12 (10%) 12
BRCA1 3 (3%) 3
BRCA2 13 (11%) 1 12
BRIP1 7 (6%) 1 6
CHEK1 3 (3%) 3
CHEK2 4 (3%) 1 3
FANCA 9 (8%) 9
FANCC 3 (3%) 3
FANCD2 11 (9%) 11
FANCE 6 (5%) 6
FANCF 3 (3%) 3
FANCG 1 (1%) 1
FANCI 6 (5%) 6
FANCL 4 (3%) 4
FANCM 9 (8%) 9
MRE11A 2 (2%) 2
NBN 9 (8%) 9
PALB2 6 (5%) 6
RAD50 3 (3%) 3
RAD51 1 (1%) 1
RAD51C 2 (2%) 2
RAD51D 0 0
RAD52 4 (3%) 4
RAD54L 2 (2%) 2
Abbreviations: HR, homologous recombination.
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based chemotherapy in the REAL3 trial, which we found 
to be prognostic for survival in this patient population. The 
results of the current study can be considered preliminary, 
and analysis of a larger cohort is necessary in order to 
provide further validation on the hypothesized clinical 
significance of LOH. Specifically, we acknowledge 
that the small size of our data set made it impossible to 
separate the data into a training data set and one to test the 
LOH cutoff prospectively. We plan to do this in the phase 
II randomized PLATFORM trial (NCT02678182) which 
is currently running in the United Kingdom and which 
will have recruited almost one thousand patients when 
fully accrued. As immuno-oncology therapy moves to 
the fore, tumours with high levels of genomic scar which 
elicit robust immune responses may also be candidates 
for immune checkpoint therapy, and it is possible that 
combining PARP inhibition and checkpoint inhibitor 
therapy could provide long term benefits for selected 
patients [36, 37].
MATERIALS AND METHODS
From the REAL3 cohort (n=553) pre-treatment 
tumour biopsies (tissue blocks) with high tumour content 
(>30%) were selected by a pathologist. All patients 
included in this analysis had given informed consent for 
translational research. The REAL3 trial was conducted 
under national and local ethical approvals.
The Foundation Medicine T5 next-generation 
sequencing assay (Foundation Medicine, Cambridge, MA, 
USA) was used to calculate the percentage of genomic 
LOH in pretreatment biopsies, a minimum DNA input 
of 200ng is recommended for the assay [38]. This assay 
interrogates 287 cancer-related genes for mutations 
and 3543 single-nucleotide polymorphisms (SNPs) 
across the whole genome. An algorithm was developed 
to quantify the percentage of interrogable genome with 
LOH. Briefly, minor-allele frequencies of the examined 
SNPs and copy number profile across the 22 autosomal 
chromosomes were used to identify segments with LOH 
across the interrogable genome. Excluded from this 
percentage were events that were unlikely to be caused 
by HRD mechanisms, such as whole chromosome or 
chromosome-arm loss. The percentage of genomic LOH 
for each sample was calculated as the sum of the lengths 
of included LOH segments divided by the length of the 
interrogated genome.
The primary endpoint of the study was to determine 
a cut-off for LOH which separated patients into two groups 
(LOH-high and LOH-low) which were associated with 
distinct survival outcomes. To set a cutoff for separating 
samples high in genomic LOH from those low in genomic 
LOH, we performed a multi-dimensional optimization 
of parameters across all possible LOH cutoffs across the 
range of observed LOH values [39]. Across the range of 
genomic LOH 3% to 26% and in increments of 1% we 
calculated the following values; hazard ratio (HR) between 
LOH high and low populations using a Cox proportional 
hazards regression model; the likelihood ratio p-value of 
said hazard ratio; median overall and progression free 
survival (OS, PFS) in the LOH high and low groups and 
the size of the LOH-high vs. low populations captured by 
that cutoff. We selected the smallest HR with the smallest 
p-value and required sensitivity and specificity to be 
larger than 50% for both OS and PFS. From the subset 
of LOH cutoffs that meet these criteria, we chose the one 
that captured the largest patient population within these 
criteria.
Multivariate analysis of variance (MANOVA) 
was used to identify variables that could potentially 
confound any findings related to survival. The investigated 
potentially confounding variables were: age, gender, 
tumour site, disease extent, WHO performance status, 
histological subtype, and treatment group. To control 
for the effects of potentially confounding variables we 
performed an extended confounding analysis and applied 
groupwise statistical tests to the parameters above in 
the two groups, LOH-high and LOH-low. In order to 
homogenise the patient population we performed a 
sensitivity analysis in which patients who underwent 
potentially curative surgery after chemotherapy were 
censored for progression free and overall survival at the 
time of surgery.
Abbreviations
HRD: homologous recombination deficiency; LOH: 
loss of heterozygosity; MANOVA: multivariate analysis 
of variance; OS: overall survivall; PFS: progression free 
survival; USA: United States of America.
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